Divis Laboratories rose 2.36% to Rs 4415 after the company's consolidated net profit rose 91.71% to Rs 902.24 crore on 46.54% increase in net sales to Rs 2493.24 crore in Q3 December 2021 over Q3 December 2020.
Profit before tax rose 60.99% to Rs 1033.66 crore in Q3 December 2021 over Q3 December 2020.Total expenses jumped 36.85% to Rs 1476.2 crore with cost of materials consumed climbing 32.46% to Rs 901.16 crore during the period under review.
For the 9-month period ended 31 December 2021, the company earned a PAT of Rs 2066 crore on a total income of Rs 6503 crore, as against a PAT of Rs 1482 crore on a total income of Rs 5224 crore during the corresponding previous period.
Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
